I think we all, with the exception of VC, recognize that scrambler therapy works. CTTC has had a lackluster clinical trial program and has failed to devote attention to managed care and reimbursement.
I know that you felt reassured after a conversation with the CFO; however, their lack of transparency and failure to provide financial reports and/or news on a timely basis concerns me. In the several years that I have been following, CTTC fails to sell an average of one unit per month domestically. Even though it is overpriced, an organization cannot be sustained for the long term on this basis.
In looking at the new CFO's background it looks like he could either help through a turnaround or a bankruptcy. My thought is that if CTTC comes up with a large GSA contract in March, everything will be alright. If they fail to garner the GSA contract there will be a bankruptcy filing in April. Coincidentally I think this is also the time they have another contractual issue with the inventor.
I'd appreciate your thoughts, please.
